Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

BACKGROUND: Ixekizumab (IXE) is an interleukin (IL)-17A antagonist approved for the treatment of adults with moderate-to-severe psoriasis. OBJECTIVE: The objective of this study was to determine if the immune response to tetanus and pneumococcal vaccines in healthy subjects administered IXE was noni...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez, Elisa V., Bishop, Jessie L., Jackson, Kimberley, Muram, Talia M., Phillips, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696443/
https://www.ncbi.nlm.nih.gov/pubmed/29116597
http://dx.doi.org/10.1007/s40259-017-0249-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696443/
https://www.ncbi.nlm.nih.gov/pubmed/29116597
http://dx.doi.org/10.1007/s40259-017-0249-y

Ejemplares similares